問卷

TPIDB > Search Result

Search Result

篩選

List

19Cases

2025-04-01 - 2032-12-31

Not yet recruiting
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung

  • Test Drug

    Capsules Intravenous infusion Intravenous infusion

Participate Sites
18Sites

Recruiting18Sites

2023-07-01 - 2027-11-30

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting1Sites

Recruiting8Sites

2024-01-01 - 2028-09-30

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2024-04-01 - 2027-05-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2020-09-22 - 2024-03-29

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2020-11-01 - 2027-06-30

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2023-01-01 - 2029-05-19

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2023-09-01 - 2029-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

2023-12-01 - 2031-05-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Recruiting11Sites

2024-10-01 - 2034-06-01

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

1 2